Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Current Deferred Revenue: 2023-2025

Historic Current Deferred Revenue for Immunome (IMNM) over the last 2 years, with Mar 2025 value amounting to $4.0 million.

  • Immunome's Current Deferred Revenue fell 68.50% to $4.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $4.0 million, marking a year-over-year decrease of 68.50%. This contributed to the annual value of $6.9 million for FY2024, which is 33.85% down from last year.
  • Per Immunome's latest filing, its Current Deferred Revenue stood at $4.0 million for Q1 2025, which was down 42.16% from $6.9 million recorded in Q4 2024.
  • Immunome's 5-year Current Deferred Revenue high stood at $18.2 million for Q1 2023, and its period low was $4.0 million during Q1 2025.
  • For the 3-year period, Immunome's Current Deferred Revenue averaged around $12.1 million, with its median value being $12.6 million (2024).
  • Data for Immunome's Current Deferred Revenue shows a maximum YoY plummeted of 68.50% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Immunome's Current Deferred Revenue stood at $10.5 million in 2023, then crashed by 33.85% to $6.9 million in 2024, then slumped by 68.50% to $4.0 million in 2025.
  • Its Current Deferred Revenue stands at $4.0 million for Q1 2025, versus $6.9 million for Q4 2024 and $9.7 million for Q3 2024.